Celiac Disease News and Research RSS Feed - Celiac Disease News and Research

Celiac disease is an inherited autoimmune disorder where gluten has been identified as the environmental trigger of the disease. Gluten is an ingested protein found in wheat, barley and rye. Gluten is broken down into gliadin which can pass through the intestinal epithelial barrier during times of increased intestinal permeability. The ingestion of gluten causes an immune response which triggers an inflammatory reaction in the small intestine. This then causes damage to the villi in the small intestine and can lead to total villous atrophy in celiac disease. This results in varying symptoms such as fatigue, skin rash, anemia, fertility issues, joint pain, weight loss, pale sores inside the mouth, tooth discoloration or loss of enamel, depression, chronic diarrhea or constipation, gas and abdominal pain. The immunology and nutritional abnormalities in celiac disease can potentially result in long- term complications such as osteoporosis, refractory sprue, small intestinal cancer, and lymphoma.

Celiac disease is a growing public health concern, affecting approximately 3 million people in the United States and over 6.5 million people worldwide. The only current management of celiac disease is complete elimination of gluten from the diet, which can be very difficult to implement in practice. Additionally, the response to the gluten-free diet is poor in up to 30% of patients, and dietary nonadherence is the chief cause of persistent or recurrent symptoms.
Arsenic levels exceed in some rice-based foods, can affect celiac disease sufferers

Arsenic levels exceed in some rice-based foods, can affect celiac disease sufferers

Rice is one of the few cereal grains consumed by people with celiac disease, as it does not contain gluten. However, it can have high concentrations of a toxic substance – arsenic – as revealed by the analyses of flour, cakes, bread, pasta and other foods made with rice, conducted by researchers from the Miguel Hernández University of Elche, Spain. [More]
Australian researchers use hookworms to reduce symptoms of celiac disease

Australian researchers use hookworms to reduce symptoms of celiac disease

Australian researchers have achieved groundbreaking results in a clinical trial using hookworms to reduce the symptoms of celiac disease. [More]
Avalon Ventures, GSK jointly launch two new early-stage life science companies

Avalon Ventures, GSK jointly launch two new early-stage life science companies

Avalon Ventures today announced the launch of two new companies formed through its collaboration with GlaxoSmithKline to fund and launch up to 10 early-stage life science companies. [More]
New version of drug successfully treats lupus in mice

New version of drug successfully treats lupus in mice

Expanding on his work with a new drug that successfully treated lupus in mice, a biomedical engineer at the University of Houston has received a $250,000 grant to expand his research to a new version of the drug in an effort to treat a wider range of autoimmune diseases. [More]
Researchers develop new "nanojuice" to help doctors better identify human gut

Researchers develop new "nanojuice" to help doctors better identify human gut

Located deep in the human gut, the small intestine is not easy to examine. X-rays, MRIs and ultrasound images provide snapshots but each suffers limitations. Help is on the way. [More]
Screening genetically susceptible infants can help detect celiac disease at a very early age

Screening genetically susceptible infants can help detect celiac disease at a very early age

Physicians from the University of Colorado School of Medicine in collaboration with an international team of researchers have demonstrated that screening of genetically susceptible infants can lead to the diagnosis of celiac disease at a very early age. [More]
BioLineRx announces in-licensing of BL-1110 compound for treatment of neuropathic pain

BioLineRx announces in-licensing of BL-1110 compound for treatment of neuropathic pain

BioLineRx Ltd., a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today it has in-licensed BL-1110, a novel compound for the treatment of neuropathic pain. [More]
Gluten-free diet can improve 'brain fog' in individuals with celiac disease

Gluten-free diet can improve 'brain fog' in individuals with celiac disease

Individuals with celiac disease often experience 'brain fog' in addition to intestinal problems, but a new study shows that adhering to a gluten-free diet can lead to improvements in cognition that correlate with the extent of intestinal healing. [More]
AtomoRapid blood test device named Best in Show at 2014 MDEA program

AtomoRapid blood test device named Best in Show at 2014 MDEA program

Atomo Diagnostics' multi-award winning AtomoRapid™ HIV last night was awarded Best in Show, and the winner of the In Vitro Diagnostics Category, at the 17th Medical Design Excellence Awards (MDEA), held in New York. [More]
BioLineRx gets Notice of Allowance for patent related to new treatment for celiac disease

BioLineRx gets Notice of Allowance for patent related to new treatment for celiac disease

BioLineRx Ltd., a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that a Notice of Allowance has been issued by the United States Patent and Trademark Office (USPTO) for a patent claiming the composition of BL-7010, a novel polymer for the treatment of celiac patients. [More]
Cell Science Systems launches new blood test profile for GI disorders

Cell Science Systems launches new blood test profile for GI disorders

Distinguishing the cause of gut disorders can be complicated. Therefore, Cell Science Systems, Corp. today announced the launch of a new test to help clinicians reach a diagnosis; and, suggest dietary strategies to improve whatever gut malady a person may have. [More]
BioLineRx announces financial results for Q1 2014, provides operational update

BioLineRx announces financial results for Q1 2014, provides operational update

BioLineRx, a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, today reported its financial results for first quarter ended March 31, 2014. [More]
Study finds increased risk of hospitalization for heart failure in IBD patients

Study finds increased risk of hospitalization for heart failure in IBD patients

Heart failure hospitalisation more than doubles during inflammatory bowel disease (IBD) flares, according to a study of more than 5 million Danish people. The research was presented today at the Heart Failure Congress 2014, held 17-20 May, in Athens, Greece. [More]
Autoimmune epilepsy diagnostics: an interview with Dr. Joseph J. Higgins, Medical Director, Neurology, Athena Diagnostics, a business of Quest Diagnostics

Autoimmune epilepsy diagnostics: an interview with Dr. Joseph J. Higgins, Medical Director, Neurology, Athena Diagnostics, a business of Quest Diagnostics

Epilepsy is a group of neurological disorders often characterized by seizures and cognitive impairment due to electrical disturbances in the brain. [More]
Oral health: The gateway to your overall health

Oral health: The gateway to your overall health

If the eyes are the windows to your soul, then your mouth is the gateway to your overall health. Research has found a surprising number of links between the state of your oral health and your overall health. [More]
AGA Research Foundation announces 2014 AGA Research Scholars

AGA Research Foundation announces 2014 AGA Research Scholars

The American Gastroenterological Association Research Foundation is pleased to announce the 2014 AGA Research Scholars. The AGA Research Scholar Awards program, launched in 1984, enables young investigators to develop independent and productive research careers in digestive diseases. This year, the AGA Research Scholar Awards fund an additional year allowing for three consecutive years of funding. [More]
Prevalence of celiac disease on the rise among children with irritable bowel syndrome

Prevalence of celiac disease on the rise among children with irritable bowel syndrome

There appears to be an increased prevalence of celiac disease among children with irritable bowel syndrome (IBS). [More]
New hypothesis about emergence of Parkinson's disease

New hypothesis about emergence of Parkinson's disease

The cause of neuronal death in Parkinson's disease is still unknown, but a new study proposes that neurons may be mistaken for foreign invaders and killed by the person's own immune system, similar to the way autoimmune diseases like type I diabetes, celiac disease, and multiple sclerosis attack the body's cells. [More]
BioLineRx to initiate Phase 1/2 clinical trial on new drug candidate for CML treatment

BioLineRx to initiate Phase 1/2 clinical trial on new drug candidate for CML treatment

BioLineRx, a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that Prof. Arnon Nagler, Director of the Hematology Division and Bone Marrow Transplantation Center at Sheba Medical Center, Israel, has received final regulatory approval to evaluate BioLineRx's BL-8040 as a treatment for chronic myeloid leukemia (CML) in a Phase 1/2 clinical study. [More]
Researchers show Elafin protein plays key role against inflammatory reaction typical of celiac disease

Researchers show Elafin protein plays key role against inflammatory reaction typical of celiac disease

Scientists from INRA and INSERM (France) in collaboration with scientists from McMaster University (Canada) and the Ecole polytechnique fédérale of Zurich (Switzerland) have shown that Elafin, a human protein, plays a key role against the inflammatory reaction typical of celiac disease (gluten intolerance). [More]